Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company developing cancer therapies based on PLK1 inhibition, with its lead asset onvansertib in multiple clinical programs. The CRDF news page on Stock Titan aggregates company announcements, clinical data updates, financial results and investor event participation so readers can follow how the onvansertib development story evolves over time.
News coverage for Cardiff Oncology frequently highlights clinical trial milestones, such as enrollment completion and data readouts from the randomized Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer. Press releases also describe results from investigator-initiated studies, including onvansertib in combination with paclitaxel in metastatic triple negative breast cancer and monotherapy use in chronic myelomonocytic leukemia, as well as data presented at major scientific meetings like ASCO and ASH.
Investors and observers can also find quarterly financial results and business updates, where Cardiff Oncology reports on research and development spending, cash runway and key operational highlights, alongside commentary on the progress of onvansertib across different tumor types. In addition, the company regularly announces participation in healthcare and investor conferences, including fireside chats, corporate presentations and one-on-one meetings hosted by firms such as Piper Sandler, Guggenheim, Stifel, Wells Fargo, Morgan Stanley and others.
This news feed offers a centralized view of Cardiff Oncology’s disclosures, from clinical efficacy and safety data to patent developments and leadership changes. Readers interested in oncology drug development, PLK1 inhibition, or the CRDF ticker can use this page to track Cardiff Oncology’s ongoing activities and key communications to the market.
Cardiff Oncology, Inc. (Nasdaq: CRDF) announces Dr. Mark Erlander will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The company focuses on developing onvansertib, a first-in-class Polo-like Kinase 1 inhibitor for challenging cancers such as KRAS-mutated colorectal cancer and pancreatic cancer. Dr. Erlander's presentation is scheduled for June 1 at 4:00 PM ET. A replay will be available on the Cardiff Oncology website post-event. The company aims to improve cancer treatment responses and overall patient survival using advanced biomarker technology.
Cardiff Oncology (Nasdaq: CRDF) reported a strong start to 2021, highlighted by progress in clinical trials involving onvansertib for treating KRAS-mutated cancers, including colorectal and pancreatic cancers. The company raised $20 million through a common stock sale to support clinical development. Recent data show promising outcomes, with a median progression-free survival of 9.4 months in a metastatic colorectal cancer trial, significantly better than historical controls. Operating expenses rose to $5.5 million, reflecting advancements in drug development and clinical activities.
Cardiff Oncology, Inc. (CRDF) announced positive results from its ongoing Phase 1b/2 trial of onvansertib for KRAS-mutated metastatic colorectal cancer (mCRC). The trial reported a 39% overall response rate, with a median progression-free survival (mPFS) of 9.4 months, significantly surpassing historical mPFS rates. The treatment showed good tolerability with no major toxicities. Biomarker analyses indicate the potential of plasma KRAS mutant allelic frequency in predicting patient response. Upcoming results from the Phase 2 trial are anticipated later this year.
Cardiff Oncology (Nasdaq: CRDF) announced findings from its Expanded Access Program (EAP) for onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC) at the AACR Annual Meeting 2021. The program enrolled patients who failed multiple standard therapies, showing a median progression-free survival (mPFS) of 5.6 months, exceeding historical controls. 62.5% had a >50% decrease in KRAS MAF after one treatment cycle, indicating durable responses. Onvansertib was well-tolerated with no serious adverse events reported. The EAP has reached capacity and is no longer accepting new participants.
Cardiff Oncology (Nasdaq: CRDF) announced findings from its ongoing Phase 2 trial of onvansertib in mCRPC, presented at the AACR Annual Meeting 2021. The study reveals that the androgen receptor signaling inhibitor abiraterone enhances the efficacy of onvansertib by upregulating mitosis-related genes. These results support the hypothesis that combining these drugs could improve clinical outcomes for resistant patients. The poster presentation highlighted a specific gene signature that may predict patient responses, indicating a potential for precision medicine in ongoing trials.
Cardiff Oncology (CRDF), a clinical-stage biotech firm, is set to host a webinar on April 12, 2021, at 11 a.m. ET, focusing on onvansertib for treating KRAS-mutated metastatic colorectal cancer. Featured speakers include KOLs Dr. Daniel H. Ahn and Dr. Manish R. Sharma, who will address current treatment options and unmet needs. The CEO, Dr. Mark Erlander, will provide a corporate update. Cardiff is currently conducting a Phase 1b/2 trial assessing onvansertib in combination with standard chemotherapy for KRAS-mutated mCRC.
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotech firm, announced that CEO Dr. Mark Erlander will present at the Oppenheimer 31st Annual Healthcare Conference from March 16-18, 2021. Key areas of focus include their investigational drug, onvansertib, aimed at treating several cancers, including KRAS-mutated colorectal cancer and pancreatic cancer. The presentation is scheduled for March 18, 2021, from 11:20 AM to 11:50 AM ET, and a replay will be available afterward on their website.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company, announced two abstracts to be presented at the AACR Annual Meeting 2021 from April 10-15, 2021. The first abstract focuses on the Expanded Access Program for their PLK1 inhibitor onvansertib in treating KRAS-mutant metastatic colorectal cancer, showing over 50% decrease in KRAS mutant allelic frequency in several patients. The second highlights preclinical studies on the synergy between onvansertib and abiraterone in treating prostate cancer. Full abstracts will be available online during the event.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company, announced its presentation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand starting at 7 a.m. ET on March 9. Cardiff specializes in developing treatments for aggressive cancers, including KRAS-mutated colorectal cancer and pancreatic cancer, with their investigational drug, onvansertib, being a key focus. The company will also hold one-on-one meetings with investors during the conference.
Cardiff Oncology (Nasdaq: CRDF) reported key highlights and financial results for Q4 and FY 2020, achieving significant clinical milestones. The company raised over $100 million, providing a solid financial foundation. Promising data from the mCRC program indicate onvansertib's potential, contributing to a 86% clinical benefit rate in evaluated patients. They plan to initiate a Phase 2 trial in PDAC in 2021 after receiving FDA clearance. Financially, cash reserves stood at $131 million, with increased R&D and SG&A expenses reflecting ongoing clinical endeavors.